Use for 1,3-propanediol derivatives
AssigneeNovartis AG
InventorsSylvain Cottens, Robert Paul Hof, Roland Wenger
Life of this patent
Estimating the term…
Abstract
Use of a compound of formula (I) wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.
Claims23
A method of preventing or treating chronic rejection in a patient receiving an organ or tissue allo-or xeno- transplant, comprising administering to the patient an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is an optionally substituted straight or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and
- each of R2, R3, R4 and R5 is independently H or lower alkyl.
A kit or package for preventing or treating manifestations of chronic rejection in a patient receiving an organ or tissue allo- or xeno- transplant comprising an effective amount of a compound of formula I or its pharmaceutically acceptable salt:
- R1 is an optionally substituted straight or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and
- each of R2, R3, R4 and R5 is independently H or lower alkyl,
- and an effective amount of a second immunomodulatory or anti-inflammatory agent.
A method of preventing or treating chronic rejection in anallograft recipient, comprising administering to the recipient an effective amount of 2-amino-2-[2-(4octylphenyl)ethyl]-1,3-propanediol or its pharmaceutically acceptable salt, optionally with an effective amount of a second immunomodulatory or anti-inflammatory agent.
A method of preventing or treating chronic rejection in an allograft recipient, comprising administering to the recipient an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is an optionally substituted straight or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and
- each of R2, R3, R4 and R5 is independently H or lower alkyl.
A method of preventing or treating chronic rejection in a xenograft recipient, comprising administering to the recipient an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is an optionally substituted straight or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and
- each of R2, R3, R4 and R5 is independently H or lower alkyl.
Dependencies are inferred from the claim text.